News and Trends 21 Jun 2017 British Biotech Tops up its Cancer Pipeline with New TCR Therapy Cell Medica just acquired Catapult Therapy TCR, set up by UK’s CGT Catapult, gaining the rights to its TCR therapy candidate to treat solid tumors. Cell Medica says it’s all set to leverage its Dominant T cell receptor (TCR) platform technology, which the company licensed from University College London (UCL) last year, to enhance existing T cell […] June 21, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jun 2017 Swedish Biotech publishes Long-Term Data on a Dendritic Cell Therapy for Cancer Immunicum has reported new data on long-term follow-up of patients treated with ilixadencel, a unique dendritic cell therapy against cancer. Immunicum is a Swedish biotech developing a cell-based therapy against cancer. The company has just published in the Journal for Immunotherapy for Cancer detailed results from a Phase I/II trial evaluating its lead candidate ilixadencel. The cell […] June 20, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 24 May 2017 Seed Funding for a German Cell Therapy to Prevent Transplant Rejection TolerogenixX has proved that it can get rid of immunosuppressants in organ transplants in Phase I and secured seed funding from High-Tech Gründerfonds. TolerogenixX is a startup from the Heidelberg University Hospital that develops personalized immunosuppression therapies. Its cell therapy technology has just passed Phase I, where it showed an “impressive efficacy” in preventing the rejection of […] May 24, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 11 May 2017 Celyad gets FDA Fast Track to Tackle Heart Failure with Cell Therapy Celyad has received Fast Track Designation from the FDA for C-Cure, a cell therapy aimed to treat heart failure with the patient’s own stem cells. Celyad is confident that the announcement of Fast Track Designation from the FDA will help it accelerate the search for a partner to develop C-Cure, a cell therapy for ischemic […] May 11, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 12 Apr 2017 Taking Cell Therapy one Step Further with this Boost Reagent Cell therapy is revolutionizing medicine, here’s how the latest technology can help overcome the major challenges stopping it from taking over the market. Offering unprecedented possibilities to treat some of the most challenging diseases, cell therapy is stealing the show in the biotech space. Strimvelis, the first hematopoietic stem cell (HSC) gene therapy is already […] April 12, 2017 - 4 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Interview 16 Mar 2017 “In the Coming Decade, Off-the-Shelf Cell Therapy will Become a Reality” David Sourdive, co-founder of Cellectis, discusses his pioneering work developing off-the-shelf CAR-T for cancer and the future directions of cell therapy. Last week I had the opportunity to attend the World ADOPT Summit and hear from some of the world leaders in cell therapy. There I met David Sourdive, co-founder and EVP Technical Operations at Cellectis, […] March 16, 2017 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Mar 2017 New Cardiac Stem Cell Therapy passes Phase I/II Trials TiGenix announces positive one-year results for its phase I/II trial of donor-derived cardiac stem cell therapy in acute myocardial infarction (AMI). The Belgian biotech TiGenix is developing allogeneic stem cell therapies. Now the company has announced that its cardiac stem cell therapy AlloCSC-01 reached its primary endpoints in a phase I/II trial. In 2015, the company acquired Coretherapix in a €292M deal for its allogeneic cardiac stem […] March 13, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jan 2017 It’s Not Just Regulations: 9 Other Reasons Advanced Therapies Fail For advanced therapy medicinal products (ATMPs), the regulatory process is a major challenge to reach the market; but it’s only part of the picture. Here are the top 9 other pre-approval reasons these cell and gene therapies fail. Sound Scientific Rationale + Good Product = Successful Outcome.” Paula Salmikangas, Committee for Advanced Therapies (CAT) Chairman […] January 18, 2017 - 7 minutesmins - By Timothé Cynober Share WhatsApp Twitter Linkedin Email
News and Trends 3 Jan 2017 New German Immuno-oncology Partnership takes on Solid Tumors TCR2 Therapeutics is initiating a partnership with academia to boost its TCR technology with the aim of overcoming the huge challenges of treating solid tumors. TCR2 Therapeutics, a Boston immuno-oncology startup launched in 2015 and funded by the Munich biotech mafia, is starting the year with a multi-year collaboration with the University Hospital of Ludwig-Maximilians-University (LMU) in, […] January 3, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 23 Dec 2016 The 8 Biggest Biotech Medical Fails of 2016 in Europe Although 2016 has brought plenty of good news in medical advances, biotech is an industry where failure is part of the game. Here’s a list of medical fails in biotech to learn from this year. Unfortunately, 2016 has not been a good year for pharma, with revenues in the top companies falling, the lowest number […] December 23, 2016 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2016 The Munich Biotech Mafia expand to the US with a New TCR Startup TCR2 Therapeutics was backed by the Munich biotech mafia, a group of wealthy veteran biotech leaders that seem to be taking over the promising immuno-oncology field. TCR2 Therapeutics has kicked off with a €41.2M ($44.5M) Series A round led by MPM Capital in the US and F2 Ventures in London. The new company, based in Boston, […] December 8, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Nov 2016 Meet the CEO making the Next Generation of Gene Therapies Possible How do you solve a problem like lentiviral vector infections? CEVEC has done it. We sat down with the CEO, Frank Ubags, to talk about his company’s success. The last few decades have not been kind to gene therapy companies, but the field seems to be on the edge of a renaissance with adenoviral vectors […] November 16, 2016 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email